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ABSTRACT 
Fabrication of Nanoparticles to treat Methicillin-resistant Staphylococcus aureus 
Catriona Kinane 
Department of Biochemistry 
Texas A&M University 
 
Research Advisor: Dr. Carolyn Cannon 
Department of Microbial Pathogenesis & Immunology 
 
Staphylococcus aureus (SA) lung infections are a major problem for patients with cystic fibrous 
(CF). As these infections are difficult to treat, they can be life-threatening.1 Moreover, 
methicillin-resistant Staphylococcus aureus (MRSA) strains have become more prevalent and 
often exhibit resistance to first line antibiotics, including vancomycin, clindamycin, and 
trimethoprim/sulfamethoxazole.2 A natural product, MC21-A (C58), from a marine bacteria, 
Pseudoalteromonas phenolica, has potent activity against MRSA. However, the compound is 
hydrophobic; thus, delivery in an aqueous solution is problematic.3 In order to optimize the 
efficacy of this drug candidate to treat MRSA lung infections, it must pass through the thick 
mucus in the CF airway to reach the bacteria. Encapsulating C58 in a polymeric nanoparticle can 
improve penetration into and retention in mucus and bacterial biofilms. In particular, 
nanoparticles coated with polyethylene glycol (PEG) have been shown to rapidly penetrate 
human mucus.4  We have developed a simple, scalable method for production of poly (lactic-co-
glycolic acid) (PLGA) nanoparticles coated with PEG that allows large-scale production of this 
“workhorse” nanoparticle system. These nanoparticles will allow further testing of this drug and 
other potential candidates to proceed to clinical testing for treatment of MRSA lung infections in 
CF patients. 
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NOMENCLATURE  
 
CF- cystic fibrosis  
PLGA – poly(lactic-co-glycolic acid) 
PEG- polyethylene glycol 
MRSA- methicillin-resistant Staphylococcus aureus  
SA- Staphylococcus aureus  
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CHAPTER I  
INTRODUCTION 
 
Cystic fibrosis (CF) is the most common, fatal genetic disease among Caucasians in the United 
States, affecting an estimated 30,000 people. 1 It is inherited in an autosomal recessive pattern 
and affects multiple organs including the lungs, pancreas and gastrointestinal tract.5  Mutations 
in the cystic fibrosis transmembrane conductance regulator (CFTR) gene are responsible for this 
disease; the gene codes for the CFTR protein, which is a chloride channel. Patients with CF 
produce thick and sticky mucus that clogs the lungs. Mucus also blocks the pancreatic ducts, 
which stops digestive enzymes from reaching the intestine. This ion channel, CFTR, is expressed 
on the surface of the airway epithelial cells and is responsible for the transport of chloride ions 
into the airway in the non-CF population. The chloride ions are followed by sodium ions and 
water molecules follow the salt into the airway in order to maintain the ionic and osmotic 
balance; this migration of NaCl and water results in the lining of the airway by a hydrated 
mucous layer. In CF patients, CFTR is mutated and the chloride ion transport is reduced or 
absent. This reduced or absent chloride transport results in the absence of water transport leading 
to the development of thick and sticky mucus that lines the airway. The thick mucus is an ideal 
medium for bacteria to grow including Pseudomonas aeruginosa and Staphylococcus aureus. 
Indeed, the lungs are chronically infected and have to be treated with multiple courses of 
antibiotics each year.5,6 Accordingly, the bacteria become resistant to standard-of-care antibiotics 
and new antibiotics that can penetrate the airway mucus are warranted.   
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The prevalence of methicillin-resistant Staphylococcus aureus (MRSA) lung infections has 
escalated among cystic fibrosis patients in the past two decades.2 Although outcomes of MRSA 
infection in CF patients can vary, MRSA has recently been shown to constitute an independent 
risk factor for mortality.1 Treatment of these infections is complicated by the increasing 
antibiotic resistance.2 Other antibiotics including linezolid and daptomycin have been developed 
to address the increasing prevalence of MRSA.7 However, resistance to these new antibiotics has 
already been seen.8 Vancomycin has been the treatment of choice for serious MRSA infections 
since 1958. However, its overuse has led to the emergence of vancomycin-intermediate and -
resistant MRSA.9 While the need for new antibiotics to treat MRSA is urgently needed, the rate 
of the Food and Drug Administration (FDA) approval of new antibiotics to address this need is 
declining. To further complicate the picture, the growth of MRSA in biofilms embedded in the 
thick, dehydrated mucus found in the airways of CF patients is problematic to treat due to 
inherent resistance of bacteria in biofilm growth mode, as well as difficulty in delivering high 
concentrations of antibiotics to the site of infection. For example, the gold-standard antibiotic for 
MRSA infections, vancomycin, has poor penetration into the lung, in general, and through 
mucus and biofilms, in particular. 10  Thus, new treatments for MRSA lung infections are 
needed. 
 
Drug Development  
A natural product, MC21-A (or C58), isolated from a marine bacterium, Pseudoalteromonas 
phenolica O-BC30(T), has potent activity against MRSA. This promising antimicrobial agent 
eradicates MRSA at a higher rate compared to vancomycin, without killing human cells.3,11  
Recent improvements in the production of C58 will allow for the generation of sufficient 
quantities in order for this drug to be used in clinical studies.  In vitro studies by the Cannon 
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group have verified the antimicrobial activity of C58. Compared to vancomycin, C58 
demonstrates superior activity against planktonic, as well as biofilm associated MRSA.  
 
Nanoparticle and Drug Delivery  
Using nanoparticles to deliver drugs is an intense area of research that has been successfully 
translated to the clinic. For example, in 2013, the FDA approved a paclitaxel albumin-stabilized 
nanoparticle formulation for the treatment of metastatic adenocarcinoma of the pancreas. This 
formulation prolongs the stability and the action of the chemotherapeutic agent, paclitaxel.12  The 
approval of paclitaxel albumin-stabilized nanoparticle formulation for the treatment of this fatal 
cancer was based on the demonstration of improved overall survival in a clinical trial of patients 
with metastatic pancreatic cancer.  
 
Nanoparticles can be delivered by different routes including intravenous and aerosol. Indeed, 
nanoparticles can deliver antibiotics to the lungs via either an intravenous or inhaled route.10 The 
latter routes is more highly desired, as it limits the exposure of the other organs to the delivered 
medication.  
 
Nanoparticles can be used to target drugs to specific locations in the body by altering the 
nanoparticles’ surface qualities. Each nanoparticle system must be optimized to achieve the 
desired targeted delivery. To achieve bacterial killing of MRSA in the biofilms of the CF lung, 
C58 must penetrate the thick mucus in which the microorganisms are embedded. Airways mucus 
normally traps and removes foreign particles such as nanoparticles via mucociliary clearance.13  
Thus, it is necessary to design nanoparticles capable of rapid penetration through mucus in order 
to avoid swift clearance from the airway. Nanoparticles composed of poly(lactic-co-glycolic 
acid) and coated with polyethylene glycol (PEG) have been shown to rapidly penetrate human 
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mucus and are likely to evade removal from the airway by mucociliary clearance.4  Thus, 
encapsulating C58 in PLGA-PEG nanoparticles should improve penetration into mucus and 
optimize the efficacy of this drug candidate to treat CF MRSA lung infections.  
 
Nanoparticles can be generated by a number of techniques including nanoprecipitation and 
emulsion solvent evaporation. The nanoprecipitation technique has been shown to be superior for 
loading of nanoparticles with water insoluble drugs such as C58.14 Recently, there has been 
further refinement of the nanoprecipitation method to generate particle size less than 150 nm 
with narrow distribution of size; these smaller particles are likely to evade mucociliary 
clearance.15 
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CHAPTER II 
METHODS 
 
Nanoparticles were fabricated using a nanoprecipitation technique. Parameters that affect 
nanoparticle size, shape, and morphology include the ratio of the polymer PLGA to the 
amphiphilic coating, poly(lactic-co-glycolic acid)-polyethylene glycol (PEG) and concentrations 
of solvent and non-solvents. Polymers PLGA and PEG were dissolved in acetonitrile of varying 
concentrations in combination with dimethyl sulfoxide (DMSO).16 The polymer solution was 
added to the non-solvent solution consisting of a surfactant, polyvinylpyrrolidone (PVP). The 
addition of polymer was performed via a drop-wise method in order to enhance nanoparticle 
formation and prevent aggregation. The ratios of PLGA and PEG, as well as the concentrations 
and combinations of solvents and non-solvent solution were optimized to achieve the desired 
nanoparticle size, shape, and morphology. In addition, particle size and charge are critical factors 
for the transition of the particle through the airway mucus/sputum. In order to assess these 
particle parameters, the resultant nanoparticle suspension was then centrifuged and washed with 
de-ionized water three times to remove PVP and aggregates of polymer. Finally, the 
nanoparticles were freeze-dried to a constant weight.  
 
Once the nanoparticle formulation was developed, the size and morphology of the nanoparticles 
were determined using scanning electron microscopy and dynamic light scattering.  The particles 
were coated with silver-palladium using a sputter-coater and imaged with a scanning electron 
microscope. Images were utilized to analyze the size and shape of the nanoparticles. The size, the 
distribution of molecular mass (polydispersity index), and surface charge were determined using 
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dynamic light scattering on a Brookhaven ZetaPlus system.  This is a non-invasive technique for 
measuring the size and size distribution of molecules in the micron and submicron region.  
 
Optimized parameters that yield nanoparticles with desirable characteristics were then used to 
formulate C58 drug loaded nanoparticles. Briefly, C58 was dissolved with the polymer solution 
and added to the non-solvent phase as described earlier. The concentration of C58 was 1%, 
2.5%, and 5% w/w to the polymer mass to yield C58 loaded PLGA nanoparticles. At the 
conclusion of these experiments, we identified the optimized, ideal conditions for generation of 
nanoparticles for delivery of antibiotics such as C58.  
 
11 
 
CHAPTER III 
RESULTS 
 
The PLGA-PEG was dissolved in various 
concentrations of acetonitrile. For some experiments, 
acetonitrile and DMSO were used in order to enhance 
the solubility of PLGA-PEG. Likewise PLGA-PEG 
was “dropped” into various concentration of the non-
solvent PVP. If suspended nanoparticles could be 
generated, the experimental conditions were deemed 
appropriate and the results of the experiment would 
be designated “pass”. If no suspendable particles 
could be generated, the experimental result was 
designated a “fail”. Thus, for each experimental 
condition, the results were reported as a pass or fail. 
Under some conditions, if nanoparticles were 
generated, but could not be suspended despite two 
attempts to do so, the results of were reported as 
“fail/pass”.  
 
For the first experimental condition, PLGA alone was used to determine if nanoparticles could 
be generated in the absence of PEG; this experiment would establish if PEG were necessary 
(Table 1). It was determined that PLGA alone (PEG free) did not generate nanoparticles using 
Table 1  PLGA in the absence of PEG 
%Acetonitrile 
(solvent) 
PLGA 
mg/mL 
% PVP 
(non-
solvent) 
Result 
80% 25 0% Fail 
80% 25 0.5% Fail 
80% 25 1% Fail 
95% 25 2% Fail 
95% 25 1% Fail 
80% 50 2% Fail 
80% 50 1% Fail 
95% 50 5% Fail 
95% 50 2% Fail 
95% 50 1% Fail 
95% 100 2% Fail 
95% 100 1% Fail 
100% 50 5% Fail 
100% 50 2% Fail 
100% 50 1% Fail 
100% 50 0.5% Fail 
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nanoprecipitation no matter what concentrations of acetonitrile or PVP were used.  It was 
concluded that PEG was needed in order to generate nanoparticles.  
 
Initially, lower concentrations of PEG 
were used in order to be cost effective. 
Thus, experiments were performed using 
0.5% PEG (Table 2). Likewise, the 
addition of 0.5% PEG did not result in the 
generation of nanoparticles. Higher 
concentrations of PEG were deemed 
necessary.  
 
 
 
Further experiments were performed with 
1% PEG (Table 3). Again, particles were not 
generated. Sequential experiments were 
performed by increasing the PEG 
concentration by 0.5% intervals until 
reaching an optimal concentration of 3% 
PEG.  
 
 
 
Table 2 – PLGA combined with 0.5% PEG. 
% Acetonitrile 
(solvent) 
PLGA 
mg/mL 
% PVP 
(non-solvent) 
Result 
100% 50 2.5% Fail 
100% 50 2% Fail 
100% 50 1.5% Fail 
 
Table 3 PLGA combined with 1% PEG. 
% Acetonitrile 
(solvent) 
PLGA 
mg/mL 
% PVP 
(non-solvent) 
Result 
80% 25 2% Fail 
80% 25 1% Fail 
95% 25 2% Fail 
95% 25 1% Fail 
80% 50 2% Fail 
80% 50 1% Fail 
95% 50 5% Fail 
95% 50 2% Fail 
95% 50 1% Fail 
100% 50 2.5% Fail 
100% 50 2% Fail 
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Ultimately, the concentration 
of PEG was increased to 
3.5% and robust particle 
formation was observed.  The 
optimal conditions for the 
generation of nanoparticles 
were: PLGA (50 mg/mL) 
combined with 3% PEG 
that was dissolved in 80% acetonitrile, which was in turn, “dropped” into 1.5% or 2.5% 
PVP (Table 4). 
 
As the solvent is critical for particle formation, we explored whether or not other solvents may 
be used. Acetonitrile was substituted with acetone or acetone plus DMF. Acetonitrile was the 
only successful solvent (Table 5).  
 
 
 
 
 
 
 
 
Table 4 
PLGA combined with 2.5% PEG 
  
PLGA combined with 3% PEG 
. 
 
 
Table 5. PLGA combined with 3% PEG 
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These particles were characterized to assess size and shape in order to determine if this method 
generated the ideal particle that could penetrate the airway mucus. A particle size of 200 nm is 
considered be the optimal nanoparticle size.4 Particle sizes in the presence and absence of drug 
(C58) were assessed (Figure 1).  5% C58-loaded particles resulted in larger particles of about 
3500 nm. 1% C58-loaded particles did not efficiently load, but were of smaller size.  Loading 
was demonstrated by light absorbance at 300 nm and 360 nm.  1% C58- loaded particles had an 
absorbance of 0.07 at 300 nm and 0.07 at 360 nm; and 5% C58-loaded particles had an 
absorbance of 0.302 at 300 nm and 0.132 at 360 nm. Thus, it can be concluded that particles 
loaded with 5% C58 could be formed by combining PLGA (50 mg/mL) with 3% PEG that was 
dissolved in 80% acetonitrile and dropped into 2% PVP.  
  
 
 
Figure 1. Define the size of C58 loaded particles 
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CHAPTER IV 
CONCLUSION 
PLGA-PEG nanoparticles can be fabricated using the nanoparticle precipitation method.  
Overall, it can be concluded that the concentration of PEG is critical for the manufacturing 
process. This conclusion is not surprising, as PEG is essential for the formation of the particle-
solution interface.  We found that 2.5% to 3% PEG was necessary, but higher concentrations 
may produce a higher particle yield with a smaller size. Further work will need to be performed 
in order to determine the optimal PEG concentration.  If higher PEG concentrations are needed, 
the cost of particle generation will increase.  Also, higher concentrations of PEG may trap C58 in 
the particle and not allow release into the mucous/biofilm. 
 
Acetonitrile was an appropriate solvent at a concentration of 80%.  Acetone or acetone plus 
DMSO are similar solvents, but did not result in particle formation. This result is a little 
disappointing, as acetone is considered a safer solvent.  Thus, particles will need to be 
thoroughly washed before human usage.  
 
Particles loaded with the antibiotic, C58, resulted in particle formation. Low concentrations of 
1% C58 resulted in a particle size of 450 nm, which is close to the target particle size 250 nm, 
but they did not efficiently load. 4  However, nanoparticles loaded with 5% C58 resulted in large 
particles of 3500 nm.  Smaller particle size and higher concentrations of antibiotics are optimal 
for penetration into the mucus and delivery of high concentrations of drug.  Further experiments 
in which the PLGA concentration is reduced so that more C58 may be packed into the particle 
core may allow for the production of particles of smaller size.  However, particles of 3500 nm 
may be workable. They will likely deposit in the small and medium size airways where the 
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infection occurs in CF patients.  Indeed, in the classical study by Gebhart et at, particles of 3500 
nm deposited at the appropriate site for the treatment of infection in the CF airway.17 There is, 
however, a disadvantage, as particles of this size are removed from the airway via mucociliary 
clearance.13 Nevertheless, the approach may be successful, because a recent publication showed 
that mucociliary clearance is reduced in patients with CF and absorbance from nanoparticles is 
enhanced.18 Thus, the larger particles loaded with 5% C58 maybe an appropriate workhorse 
particle.   
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